A phase II trial in patients with acute promyelocytic leukaemia (APML) to evaluate the effects of: all-trans retinoic acid (ATRA) combined with intensive idarubicin during induction and consolidation; subsequent intermittent all-trans retinoic acid; and molecular monitoring for evidence of minimal residual leukaemia and for evidence of incipient relapse, as measured by remission rate, relapse rate and overall survival.

DOI number 10.58109/zznv-dq19
Publisher Australasian Leukaemia and Lymphoma Group (ALLG)

Australasian Leukaemia and Lymphoma Group (ALLG)

Harry Iland (Royal Prince Alfred Hospital)

Date Made Available 2023
Dataset Individual participant data (IPD) in aggregate form
Description of Dataset

Dataset includes:

  • Data for 107 patients with newly diagnosed APL
  • Treatment involved use of all-trans retinoic acid (ATRA) combined with idarubicin
  • Demographic data
  • Diagnostic data
  • Treatment data
  • Outcome data

Australasian Leukaemia and Lymphoma Group (ALLG)

Subject (ANZSRC Category)


ANZCTR Reference ACTRN12607000410459
Dataset Access

Access can be requested via the Health Data Australia catalogue. Search for the ACTRN number in the catalogue to find datasets associated with this trial or email enquiries to info@allg.org.au